A new ultra-high-performance brain PET system allows for the direct measurement of brain nuclei as never before seen or quantified. With its ultra-high sensitivity and resolution, the NeuroEXPLORER provides exceptional brain PET images and has the potential to spur advances in the treatment of many brain diseases. This research was presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, and the grouping of images highlighting targeted tracer uptake in specific brain nuclei has been selected as the 2024 SNMMI Henry N. Wagner, Jr., Image of the Year.
Connecticut
United-states
California
New-haven
Yale-university
Henryn-wagner-jr
Heather-jacene
Richarde-carson
Center-at-yale-university
High-resolution-research-tomograph
Journal-of-nuclear-medicine
Society-of-nuclear-medicine
MELBOURNE, Australia, Oct. 20, 2022 /PRNewswire/ Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 September 2022 (Q3 2022). All figures are in AUD$ unless otherwise stated.[1] All figures are provided on an unaudited basis. Financial Summary Telix reports total revenue of $55.3 million from global sales of Illuccix, up 168% on the previous quarter ($20.6 million, Q2 2022) U.S. sales of Illuccix up 178% to $53.7 million (US$36.4 million) in second quarter of commercial sales ($19.3 million, Q2 2022) Cash balance of $117.1 million; provides 21 quarters of cash runway (based on Q3 2022 burn rate) Net operating cash outflow reduced by $20.5 million to $5.3 million, a significant reduction on the prior quarter ($25.8 million net operating cash outflow). Key factors impacting this improvement are: Customer receipts of $44.5 million, up from $5.4 million in the p
Australia
Japan
United-states
United-kingdom
Azerbaijan
Brazil
Seneffe
Waals-gewest
Belgium
China
Czech-republic
South-africa